Rich66
10-08-2010, 11:14 AM
1. Roche CEO touts 'stunning' breast, lung cancer data (http://links.mkt1985.com/ctt?kn=172&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0)
By Maureen Martino http://static.fiercemarkets.com/public/newsletter/assets/comment_ico.gif (http://links.mkt1985.com/ctt?kn=157&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0) Comment (http://links.mkt1985.com/ctt?kn=157&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0) | http://static.fiercemarkets.com/public/newsletter/assets/email_ico.jpg (http://links.mkt1985.com/ctt?kn=225&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0) Forward (http://links.mkt1985.com/ctt?kn=225&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0) | http://assets.fiercemarkets.com/public/socialicons/twitter-small.png (http://links.mkt1985.com/ctt?kn=133&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0)Twitter (http://links.mkt1985.com/ctt?kn=133&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0) | http://assets.fiercemarkets.com/public/socialicons/facebook-small.png (http://links.mkt1985.com/ctt?kn=196&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0)Facebook (http://links.mkt1985.com/ctt?kn=196&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0) | http://assets.fiercemarkets.com/public/socialicons/linkedin-small.png (http://links.mkt1985.com/ctt?kn=135&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0)LinkedIn (http://links.mkt1985.com/ctt?kn=135&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0) Hours ahead of the 2010 European Society for Medical Oncology meeting in Milan, Roche CEO Severin Schwan (photo (http://links.mkt1985.com/ctt?kn=226&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0)) is talking up data from two of his company's cancer drugs: T-DM1, a breast cancer treatment, and MetMab, a drug for lung cancer. "I think a lot of people will be very excited about what we have to present," said Schwan, as quoted by Reuters. "I think the T-DM1 results are stunning; MetMab results are stunning." The remarks were made at a press and analyst event in Tokyo.
In a head-to-head Phase II study, T-DM1 demonstrated a higher response rate and lower toxicity than Roche's blockbuster Herceptin. TheStreet notes that the results are significant since T-DM1 could eventually replace Herceptin. Immunogen is also partnered on the drug. More data on T-DM1 and MetMab will be presented at the meeting.
By Maureen Martino http://static.fiercemarkets.com/public/newsletter/assets/comment_ico.gif (http://links.mkt1985.com/ctt?kn=157&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0) Comment (http://links.mkt1985.com/ctt?kn=157&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0) | http://static.fiercemarkets.com/public/newsletter/assets/email_ico.jpg (http://links.mkt1985.com/ctt?kn=225&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0) Forward (http://links.mkt1985.com/ctt?kn=225&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0) | http://assets.fiercemarkets.com/public/socialicons/twitter-small.png (http://links.mkt1985.com/ctt?kn=133&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0)Twitter (http://links.mkt1985.com/ctt?kn=133&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0) | http://assets.fiercemarkets.com/public/socialicons/facebook-small.png (http://links.mkt1985.com/ctt?kn=196&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0)Facebook (http://links.mkt1985.com/ctt?kn=196&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0) | http://assets.fiercemarkets.com/public/socialicons/linkedin-small.png (http://links.mkt1985.com/ctt?kn=135&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0)LinkedIn (http://links.mkt1985.com/ctt?kn=135&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0) Hours ahead of the 2010 European Society for Medical Oncology meeting in Milan, Roche CEO Severin Schwan (photo (http://links.mkt1985.com/ctt?kn=226&m=3177603&r=MTg5NDA3NTY0NTcS1&b=0&j=OTgyMjc4MTMS1&mt=1&rt=0)) is talking up data from two of his company's cancer drugs: T-DM1, a breast cancer treatment, and MetMab, a drug for lung cancer. "I think a lot of people will be very excited about what we have to present," said Schwan, as quoted by Reuters. "I think the T-DM1 results are stunning; MetMab results are stunning." The remarks were made at a press and analyst event in Tokyo.
In a head-to-head Phase II study, T-DM1 demonstrated a higher response rate and lower toxicity than Roche's blockbuster Herceptin. TheStreet notes that the results are significant since T-DM1 could eventually replace Herceptin. Immunogen is also partnered on the drug. More data on T-DM1 and MetMab will be presented at the meeting.